{
    "title": "Regeneron pins hope on eczema drug as Eylea sales slow",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4207618/Regeneron-profit-edges-past-estimates.html",
    "date": "2017-02-09",
    "keywords": [
        "drug",
        "eylea",
        "grover",
        "company",
        "percent",
        "year",
        "dupixent",
        "revenue",
        "regeneron",
        "gmt",
        "divya",
        "schleifer",
        "blockbuster",
        "growth",
        "increase",
        "sarilumab",
        "praluent",
        "heart",
        "repatha",
        "email",
        "groverfeb",
        "executive",
        "leonard",
        "biotech",
        "track",
        "reliance",
        "approval",
        "treatmentseylea",
        "companys",
        "market",
        "competition",
        "thursday",
        "percentage",
        "street",
        "rise",
        "mark",
        "shift",
        "call",
        "forecast",
        "eye",
        "drugregeneron",
        "eczema",
        "arthritis",
        "streama",
        "decision",
        "march",
        "marketing",
        "application",
        "callschleifer",
        "practice",
        "industry",
        "trend",
        "percentagesprice",
        "spot",
        "abbvie",
        "criticism",
        "price",
        "prescription",
        "sas",
        "cholesterolfighter",
        "collaboration",
        "miss",
        "revenuepraluent",
        "potent",
        "injection",
        "potential",
        "health",
        "evidence",
        "attacksamgen",
        "inc",
        "trial",
        "generatedregeneron",
        "sanofi",
        "setback",
        "january",
        "judge",
        "amgenbut",
        "wednesday",
        "court",
        "injunctionexcluding",
        "share",
        "cent",
        "thomson",
        "reporting",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}